Appears on
Articles4
Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData
As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on patient-reported outcomes to carve out space for Briumvi (ublituximab) in a crowded anti-CD20 monoclonal antibody (mAb) field. There is growing importance on patient-centered outcomes as manufacturers seek competitive a
MSCopilot Detect emerges as early contender for scalable remote MS monitoring, says GlobalData
Digital biomarkers are gaining momentum in multiple sclerosis (MS) care, with new findings highlighting the potential of smartphone-based assessments to transform disability monitoring. Early evidence supporting MSCopilot Detect use underscores growing industry efforts to enable scalable, remote, and standardized disease assessment, a shift that could reshap
Commercial insurers face volatility as impending UK leadership shift triggers SME uncertainty, reveals GlobalData
Andy Burnham’s impending takeover from Sir Keir Starmer as UK Prime Minister introduces a wave of political ambiguity that could destabilize commercial insurers. Little is known about any changes Burnham will make that could impact insurance at this point. However, uncertainty is always a concern for SMEs in the UK, which could trouble commercial insurers […
